Steven Cohen Belite Bio, Inc Transaction History
Point72 Asset Management, L.P.
- $39.3 Billion
- Q1 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Belite Bio, Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 8,700 shares of BLTE stock, worth $395,850. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,700
Previous 7,700
12.99%
Holding current value
$395,850
Previous $352,000
5.4%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BLTE
# of Institutions
12Shares Held
58.3KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA16.7KShares$758,4850.0% of portfolio
-
Marshall Wace, LLP London, X010.6KShares$481,5720.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$304,8500.0% of portfolio
-
Morgan Stanley New York, NY6.09KShares$277,0950.0% of portfolio
-
Cubist Systematic Strategies, LLC Stamford, CT4.79KShares$217,8540.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.13B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...